GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Change In Working Capital

Cutia Therapeutics (HKSE:02487) Change In Working Capital : HK$-109.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Change In Working Capital?

Cutia Therapeutics's change in working capital for the quarter that ended in Dec. 2024 was HK$-9.3 Mil.

Cutia Therapeutics's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-108.7 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Cutia Therapeutics Change In Working Capital Historical Data

The historical data trend for Cutia Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Change In Working Capital Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Change In Working Capital
-41.68 -32.50 -5.93 -108.70

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Working Capital Get a 7-Day Free Trial -22.13 -31.70 25.77 -100.22 -9.31

Cutia Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-109.5 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cutia Therapeutics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutia Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Change In Working Capital
Comparable Companies
HKSE:02509 HKSE:01521 HKSE:06996 HKSE:02181 HKSE:01167 HKSE:01873 HKSE:06978 HKSE:02563 HKSE:02566 HKSE:03681 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Website
https://www.cutiatx.com
Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines